Mark Foletta

Mark Foletta is a Board Member at Dexcom. Mark has previously served as a Board Member at Regulus Therapeutics and AMN Healthcare. From April 2000 to October 2012, they were Sr. VP Finance & CFO at Amylin Pharmaceuticals.

During their time at Amylin Pharmaceuticals, Mark participated as a key team member in the negotiation of several transactions with global pharmaceutical companies. Mark led the execution of nine financing transactions, including four follow-on public common stock offerings, one common stock block trade, three convertible debt offerings and one Private Investment in Public Equity (PIPE) raising gross proceeds of over $2 billion. Mark also chaired the Operating Committee responsible for setting the business plan, updating forecasts and assessing performance versus plan.

Mark was instrumental in the commercial launch of 3 novel pharmaceutical products that generated annual revenues in excess of $700 million a time of sale. Mark also cultivated relationships with institutional investors and augmented sell-side analyst coverage for Company, growing from 3 firms in early 2000 to approximately 20 firms in 2012.

Mark Foletta has a Bachelor of Arts in Business Economics from UC Santa Barbara.